

## Lupin receives UK marketing authorisation for Luforbec

14 June 2021 | News

**Luforbec 100/6 µg pMDI is indicated for regular treatment of asthma and the symptomatic treatment of patients with severe COPD**



*Luforbec 100/6 µg pMDI is indicated for regular treatment of asthma and the symptomatic treatment of patients with severe COPD*

Lupin announced that its UK subsidiary, Lupin Healthcare (UK) has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to market Luforbec (beclometasone dipropionate/formoterol fumarate dihydrate) 100/6 µg pressurised metered-dose inhaler (pMDI), the first branded generic of Fostair (beclometasone dipropionate/formoterol fumarate dihydrate) 100/6 µg pMDI, which has the potential to offer significant cost savings for the NHS.

Luforbec 100/6 µg pMDI is indicated for regular treatment of asthma and the symptomatic treatment of patients with severe chronic obstructive pulmonary disease (COPD) (FEV1 <50 per cent predicted normal).

“We are truly delighted to receive the first marketing authorisation for generic Fostair 100/6 µg pMDI in the UK. This is an important milestone for our respiratory franchise as we expand our product offering across the globe,” said Vinita Gupta, CEO, Lupin. “At Lupin, we remain committed to serving patients suffering from respiratory diseases with quality and cost-effective treatment.”

“The approval of Luforbec 100/6 µg pMDI is a pivotal milestone for the UK and a welcome step for Lupin as we draw on our strong expertise in inhalation research and development and expand our respiratory portfolio. We are proud to support healthcare providers and patients by continuing to invest in specialised treatments for chronic diseases,” said Thierry Volle, President - EMEA, Lupin.